Mecloqualone

From WikiMD's WELLNESSPEDIA

Mecloqualone is a quinazolinone class GABAergic and is an analogue of methaqualone that was first made in the 1960s and marketed mainly in France and some other European countries. It has sedative, hypnotic, and anxiolytic properties caused by its agonist activity at the β subtype of the GABAa receptor and was used for the treatment of insomnia.

Pharmacology[edit]

Mecloqualone is a central nervous system depressant that enhances the activity of the GABA neurotransmitter. It does this by binding to the GABAa receptor at the β1 subtype, which makes the receptor have a greater affinity for the GABA neurotransmitter. This increases the frequency of opening of the associated Chloride ion channel and hyperpolarizes the membrane of the neuron. This results in a decrease in neuronal excitability.

History[edit]

Mecloqualone was developed by a team at William S. Merrell Company in the 1960s. It was introduced to the French market by Theraplix under the brand name Méquinol in 1965. It was marketed as a safer alternative to barbiturate drugs, although it has largely been withdrawn from use due to problems with abuse and dependence. It is still occasionally prescribed on a very limited basis, particularly in patients with severe insomnia who have not responded to other treatments.

Side effects[edit]

Side effects of mecloqualone include dizziness, nausea, vomiting, confusion, and seizures. Long-term use can result in tolerance, dependence, and withdrawal symptoms on discontinuation.

Legal status[edit]

Mecloqualone is a controlled substance in many countries due to its potential for abuse. In the United States, it is a Schedule I drug under the Controlled Substances Act. In Canada, it is a Schedule III drug under the Controlled Drugs and Substances Act.

See also[edit]



Sedatives and Hypnotics[edit]

Miscellaneous Agents

 

Template:Anxiolytics

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.